Since clinical trials for comparatively simple forms of stem cell therapy seem to be today's topic, here is another example:
Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial.[The] therapy, called C3BS-CQR-1, involves taking stem cells from a patient's own bone marrow and [re-programming] those cells so that they go onto becoming heart cells. The cells, known as cardiopoietic cells, are then injected back into the patient's heart through a minimally invasive procedure using a catheter, [with] the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.
The trial will recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. Studies in additional countries will commence once national regulatory approvals have been received.